Author + information
Gurm HS, Sarembock IJ, Kereiakes DJ, Young JJ, Harrington RA, Kleinman N, Feit F, Wolski K, Bittl JA, Wilcox R, Topol EJ, Lincoff AM, for the REPLACE-2 Investigators. Use of Bivalirudin During Percutaneous Coronary Intervention in Patients With Diabetes Mellitus: An Analysis From the Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 Trial. J Am Coll Cardiol 2005;45:1932–8.
In the Results section of the Abstract, the last sentence should read: “There was less minor bleeding in the bivalirudin arm in diabetic patients (12.6%) vs. 24.4%, p < 0.001), whereas no difference was seen in the incidence of major bleeding (3.0% vs. 3.3%, p = 0.69).”
In the Results section of the text, the third sentence of the Bleeding Outcomes section should read: “Among the diabetic patients, major bleeding was seen in 25 (3.0%) of patients randomized to the bivalirudin arm and 26 (3.3%) of those randomized to the GP IIb/IIIa inhibitor arm (p = 0.69), whereas among the non-diabetic patients, this occurred in 2.14% in the bivalirudin arm versus 4.42% in the GP IIb/IIIa inhibitor arm (p < 0.001).”
- American College of Cardiology Foundation